IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells.
Repository Usage Stats
HIV continues to be a major global health issue. In spite of successful prevention interventions and treatment methods, the development of an HIV vaccine remains a major priority for the field and would be the optimal strategy to prevent new infections. We showed previously that a single immunization with a SIV-based integrase-defective lentiviral vector (IDLV) expressing the 1086.C HIV-1-envelope induced durable, high-magnitude immune responses in non-human primates (NHPs). In this study, we have further characterized the humoral responses by assessing antibody affinity maturation and antigen-specific memory B-cell persistence in two vaccinated macaques. These animals were also boosted with IDLV expressing the heterologous 1176.C HIV-1-Env to determine if neutralization breadth could be increased, followed by evaluation of the injection sites to assess IDLV persistence. IDLV-Env immunization was associated with persistence of the vector DNA for up to 6 months post immunization and affinity maturation of antigen-specific memory B cells.
Published Version (Please cite this version)10.1038/s42003-018-0131-6
Publication InfoTomaras, Georgia; Ferrari, Guido; Montefiori, David; Blasi, Maria; Negri, Donatella; LaBranche, Celia; ... Klotman, Mary E (2018). IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Communications biology, 1. pp. 134. 10.1038/s42003-018-0131-6. Retrieved from https://hdl.handle.net/10161/17606.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Assistant Professor in Medicine
Dr. Blasi completed her undergraduate and Ph.D. studies in Italy at the Sapienza University in Rome. She moved to Duke for a postdoctoral position in Mary Klotman’s laboratory at the Duke Human Vaccine Institute. Her research interests focus on two major priorities in the HIV-1 field: vaccine development and latent reservoirs/ cure studies. Dr. Blasi’s work encompasses several aspects of HIV-1 research, ranging from designing and testing a novel vaccine platform base
Associate Professor of Surgery
The activities of the Ferrari Laboratory are based on both independent basic research and immune monitoring studies. The research revolves around three main areas of interest: class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity (ADCC), gene expression in NK and T cellular subsets upon infection with HIV-1. With continuous funding over the last 11 years from the NIH and Bill & Melinda Gates Foundation along with many other productive collaborations wi
Professor of Surgery
Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines. Many aspects of the
Professor in Surgery
Research in the Tomaras Laboratory in the Duke Human Vaccine Institute and Departments of Surgery, Immunology, and Molecular Genetics and Microbiology at Duke University Medical Center, focuses on the identification of immune correlates of protection for preventative vaccines and identification of the mechanisms responsible for potent inhibition of human pathogens.
Alphabetical list of authors with Scholars@Duke profiles.